Korean Cancer Study Group 
Webzine 2021 Vol.20
논문 발간현황 2020.11 - 2021.04

▶ BR10-13 | PMID : 33770643

Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13)

Cytokine Volume 142, June 2021, 155487 

 DOI: 10.1016/j.cyto.2021.155487



▶ PC13-09 | PMID : 33477423

Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study

Cancers (Basel). 2021 Jan; 13(2): 331.

 DOI: 10.3390/cancers13020331



▶ HN18-12 | PMID : 33285051

Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12

Cancer Res Treat. 2020 Dec 7

DOI: 10.4143/crt.2020.824 



▶ LU16-07| PMID : 33026712

Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07

Thorac Cancer. 2020 Dec;11(12):3482-3489 

DOI: 10.1111/1759-7714.13684



▶ BR15-10 | PMID : 33332933

Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)

Cancer Res Treat.2020 Dec 17

DOI: 10.4143/crt.2020.1246



▶ HN18-12 | PMID : 32671504

Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12

J Cancer Res Clin Oncol. 2020 Dec;146(12):3359-3369 

DOI: 10.1007/s00432-020-03316-5



▶ HN12-12 | PMID : 32963347 

Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck

Br J Cancer. 2020 Dec;123(12):1720-1729.

DOI: 10.1038/s41416-020-01074-2



▶ UN17-16

Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16)

Transl Cancer Res 2020;9(5):3222-3230 

DOI: 10.21037/tcr.2020.04.07



▶ HN13-01 | PMID : 32854649

Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)

BMC Cancer. 2020 Aug 27;20(1):813.

DOI: 10.1186/s12885-020-07297-z